ʻO ka Phase 2 Clinical Trial of Retatrutide, he Triple Hormone-Receptor Agonist, no ka mālama ʻana i ka momona.

Ke Kumu a me ka Hoʻolālā Haʻawina

ʻO Retatrutide (LY3437943) kahi lāʻau peptide hou e hoʻāla aiʻekolu mau loaʻa i ka manawa hoʻokahi: GIP, GLP-1, a me ka glucagon. No ka loiloi i kona pono a me ka palekana i nā poʻe me ka momona akā me ka ʻole o ka maʻi diabetes, ua mālama ʻia kahi hoʻokolohua 2, randomized, double-blind, placebo-controlled trial (NCT04881760). He huina o338 i komome ka BMI ≥30, a i ʻole ≥27 me ka liʻiliʻi o hoʻokahi comorbidity e pili ana i ke kaumaha, ua koho ʻia e loaʻa i kahi placebo a i ʻole retatrutide (1 mg, 4 mg me ʻelua papa manawa titration, 8 mg me ʻelua papa manawa titration, a i ʻole 12 mg) i lawelawe ʻia i hoʻokahi pule i kēlā me kēia pule e ka subcutaneous injection no 48 mau pule. ʻO kakumu hopeʻO ia ka pākēneka o ka hoʻololi ʻana o ke kaumaha o ke kino ma nā wiki he 24, me nā helu hope lua me ka hoʻololi ʻana i ke kaumaha ma nā wiki 48 a me nā paepae hoʻemi kaumaha (≥5%, ≥10%, ≥15%).

Nā Hualoaʻa Nui

• 24 pule: Loaʻa nā pākēneka liʻiliʻi i ka hoʻololi ʻana i ke kaumaha o ke kino e pili ana i ka pae kumu

  • Placebo: −1.6%

  • 1 mg: −7.2%

  • 4 mg (hui pū): −12.9%

  • 8 mg (hui pū): −17.3%

  • 12 mg: −17.5%

• 48 pule: ʻO ka pākēneka o ka hoʻololi ʻana i ke kaumaha o ke kino

  • Placebo: −2.1%

  • 1 mg: −8.7%

  • 4 mg (hui pū): −17.1%

  • 8 mg (hui pū): −22.8%

  • 12 mg: −24.2%

I nā pule he 48, ʻoi aku ka maikaʻi o ka nui o nā poʻe i loaʻa i nā paepae hoʻemi kaumaha.

• ≥5% pohō kaumaha: 27% me kahi placebo vs. 92-100% i nā hui ikaika

• ≥10%: 9% me kahi placebo vs. 73-93% i nā hui ikaika

• ≥15%: 2% me kahi placebo vs. 55-83% i nā hui ikaika

Ma ka hui 12 mg, a hiki iʻO 26% o nā mea komo i nalowale i ka ≥30% o ko lākou kaumaha kumu, ka nui o ka poho kaumaha e like me ke oki bariatric.

Palekana
ʻO nā hopena ʻino i maʻamau ʻia ʻo ka ʻōpū o ka ʻōpū (nausea, luaʻi, maʻi maʻi maʻi), maʻamau maʻamau a maʻalahi a pili i ka dosis. ʻO nā kumu hoʻomaka haʻahaʻa (2 mg titration) i hōʻemi i kēia mau hanana. Ua ʻike ʻia ka piʻi ʻana o ka puʻuwai e pili ana i ka dosage, e piʻi ana i ka hebedoma 24, a laila emi iho. ʻO ka nui o ka hoʻopau ʻana mai ka 6-16% ma waena o nā hui ikaika, ʻoi aku ka kiʻekiʻe ma mua o ka placebo.

Nā hopena
I nā mākua me ka momona me ka maʻi maʻi ʻole, hana ʻia ka subcutaneous retatrutide i kēlā me kēia pule no 48 mau puleka nui o ka hoemi ana i ke kaumaha o ke kino(a hiki i ~ 24% mean loss ma ka helu kiʻekiʻe loa), me ka hoʻomaikaʻi ʻana i nā māka cardiometabolic. Hoʻohana pinepine ʻia nā hopena ʻino o ka gastrointestinal akā hiki ke mālama ʻia me ka titration. Hōʻike kēia mau ʻike i ka pae 2 hiki i ka retatrutide ke hōʻike i kahi hōʻailona therapeutic hou no ka momona, ke kali nei i ka hōʻoia ʻana i nā hoʻāʻo nui a lōʻihi 3.